Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
Clinical trial NCT04183088 · UNKNOWN
Trial details
- NCT number
- NCT04183088
- Sponsor
- National Taiwan University Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-16
- Primary completion
- 2024-03-01
- Enrollment
- 125
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.